dadstimeon Posted December 5, 2005 Share Posted December 5, 2005 http://www.masshightech.com/displayarti ... t_ID=70457 12/05/2005 10:27 AM Novelos Therapeutics Inc., a Newton company focused on the development of therapeutics to treat cancer and hepatitis, has received approval from the Food and Drug Administration for trials of the company’s NOV-002 into a single pivotal Phase 3 study in advanced non-small cell lung cancer, in combination with first-line chemotherapy. Novelos will seek to finalize the Phase 3 study design under a Special Protocol Assessment during the first half of 2006. The primary endpoint of the pivotal study will be overall survival. Novelos was established in 1996 to commercialize two oxidized glutathione-based compounds, NOV-002 and NOV-205, for the treatment of cancer and hepatitis. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.